ICCG FEC Trial

Disease site: Breast Cancer

Treatment Modality: Chemotherapy

Status: In active follow-up

Trial 1

A randomised trial comparing cyclophosphamide, methotrexate & 5-fluorouracil (CMF) with 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in patients with node negative primary breast cancer.

Trial 2

A randomised trial comparing cyclophosphamide, methotrexate & 5-fluorouracil (CMF) with 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in premenopausal patients with node positive primary breast cancer.

The primary aim of these studies was to compare disease-free-survival and overall survival in patients treated with CMF, with that observed in patients treated with FEC. The Node Positive trial (N+) recruited 759 pre-menopausal patients between 1984-1992 and the Node Negative trial (N-) recruited 950 between 1990-2000.

A meta-analysis of the two studies is currently being undertaken and both studies remain in active follow-up.

These are International Collaborative Cancer Group (ICCG) trials (C/6/89 and C/2/84).

Publications

Marty, Coombes, Peckitt et al, 2004.J Clin Oncol 23 (Suppl): 25; Abs 592. Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate and fluorouracil (CMF) vs fluorourcil, epirubicin and cyclophosphamide (FEC) chemotherapy in early breast cancer

Marty, Hall, Wils et al, 2002. pp48b. Eavluation of tolerability of CMF versus FEC in a randomized trial in node negative poor risk primary breast cancer patients

Coombes, Bliss, Wils et al, 1996. J Clin Oncol 14: 35-45. Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomised trial